ANIP Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
ANI Pharmaceuticals Inc (ANIP) is not an immediate buy for a beginner, long-term investor with $50,000-$100,000 available for investment. The stock's technical indicators are bearish, and there are no strong proprietary trading signals to suggest a favorable entry point. While the company has shown strong revenue growth and exceeded earnings expectations in Q4 2025, the recent price trend and lack of significant positive catalysts make it prudent to wait for a better opportunity.
The technical indicators are bearish. The MACD is below 0 and negatively contracting, RSI is neutral at 43.138, and the moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading below the pivot level of 75.769, with key support at 73.32 and resistance at 78.218.
Strong Q4 2025 financial performance with a 30% YoY revenue increase and a significant recovery in net income. Adjusted EPS of $2.33 exceeded market expectations, and Guggenheim raised the price target to $124, maintaining a Buy rating.
The stock has been on a declining trend, with a 1.22% drop in the regular market and a further 2.04% decline in post-market trading. Technical indicators and moving averages suggest bearish momentum. No recent congress trading data or significant insider/hedge fund activity.
In Q4 2025, ANI Pharmaceuticals reported revenues of $247.1 million, up 29.64% YoY, and a net income of $27.49 million, recovering from a prior year's net loss. Adjusted EPS increased by 43% YoY to $2.33, surpassing consensus estimates. Gross margin improved to 50.26%, up 9.21% YoY.
Guggenheim raised the price target to $124 from $115 and maintained a Buy rating, citing increased Cortrophin sales estimates and a favorable 2026 outlook.
